Regulatory Milestones

Highlights of weekly biotech stock moves

Regulatory milestones

Look for shares of Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) to move on Monday after FDA approved an NDA late Friday for Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA). Avanir said Nuedexta is the only drug approved by FDA for the condition, which is characterized by involuntary episodes of laughing and/or crying. The stock finished last week at $2.42, down $0.46.

Pharming Group N.V. (Euronext:PHARM) was unchanged at €0.25 last week after the EC approved an MAA for Ruconest to treat acute attacks of hereditary angioedema (HAE). Marketing and distribution partner Swedish Orphan Biovitrum AB (SSE:SOBI) was down SEK0.90 to SEK40.10 on the week.

Clinical milestones

Almirall S.A. (Madrid:ALM) fell €1.20 (15%) to €6.80 on Friday after it and partner Forest Laboratories Inc. (NYSE:FRX) reported data from the Phase III ACCORD COPD II trial of aclidinium bromide to treat chronic obstructive pulmonary disease (COPD). The

Read the full 1413 word article

How to gain access

Continue reading with a
two-week free trial.